{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.6","value":"5.3"},{"groupId":"OG001","spread":"5.3","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"description":"Post-treatment endocrine function was measured by laboratory assessment of the thyroid stimulating hormone (TSH). The mean TSH will be reported.","dispersionType":"Standard Deviation","groups":[{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the LDCSI arms (Treatment Arms I or II) and with a post-treatment TSH value.","id":"OG000","title":"Low-dose Craniospinal Radiation (LDSCI)"},{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the SDCSI arms (Treatment Arms III or IV) and with a post-treatment TSH value.","id":"OG001","title":"Standard-dose Craniospinal Radiation (SDCSI)"}],"paramType":"MEAN","populationDescription":"Only eligible \\& evaluable pts 3-7 years of age were included. Pts with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). 11 and 8 LDSCI and SDCSI pts were NE, respectively, leaving 116 vs 110 for this comparison. Of these, 89 LDSCI and 79 SDCSI pts had post-treatment TSH values available and were included.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Post-treatment Endocrine Function by CSI Group","type":"SECONDARY","unitOfMeasure":"uU/ml"}